Trials / Terminated
TerminatedNCT05226533
Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.
A Phase 2, Double Blind, Randomized, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of DWRX2003 in Combination With Remdesivir Following Intramuscular Administration in Moderate-Severe COVID-19 Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWRX2003 | Intramuscular injection of DWRX2003 |
| DRUG | Placebo | Intramuscular injection of placebo |
Timeline
- Start date
- 2022-03-31
- Primary completion
- 2022-12-16
- Completion
- 2022-12-21
- First posted
- 2022-02-07
- Last updated
- 2023-02-10
Locations
3 sites across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT05226533. Inclusion in this directory is not an endorsement.